[Estrogen metabolism and hormone substitution in the climacteric].
Report about the metabolism of estrogens in the postmenopausal period and the hormone replacement therapy. The indications and contraindications for the estrogen- and estrogen-progesterone-therapy were discussed. Osteoporosis in the aging women constitutes a major public health and socio-economic importance than the climacteric syndrome.
D000328:Adult; D000368:Aged; D002979:Climacteric / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004958:Estradiol / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000009:adverse effects / Q000627:therapeutic use*; D004964:Estriol / Q000627:therapeutic use; D004967:Estrogens / Q000378:metabolism*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy; D045167:Progesterone Congeners / Q000627:therapeutic use; D045165:Testosterone Congeners / Q000627:therapeutic use
D045166:Estradiol Congeners; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D045165:Testosterone Congeners; D004997:Ethinyl Estradiol; D004958:Estradiol; D004964:Estriol
Estrogenstoffwechsel und Hormonsubstitution im Klimakterium.